NeoGenomics sets release of Q3 2022 earnings statement for November 8, 2022

FT. Myers, FL / ACCESSWIRE / October 13, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), A leader in cancer-focused genetic testing and global contract research services, today announced that it plans to release its financial results for the third quarter of 2022 on Tuesday, November 8, 2022.

The company has scheduled a webcast and conference call to discuss Q3 2022 results on Tuesday, November 8, 2022 at 8:30 AM EST. Interested investors should call (888) 506-0062 (domestic) and (973) 528-00117 (international) at least five minutes prior to the call. The participant’s provided access code for this call is 188444. The conference call return will be available until 8:30 a.m. EDT on November 22, 2022, and can be reached by calling (877) 481-4010 (local) and (919) 882-2331 (international). The operating conference ID number is 46818. The webcast can be accessed under the Investor Relations section of our website at The web team archive will be available until 8:30 AM EST on November 8, 2023.

About NeoGenomics, Inc.

NeoGenomics, Inc. Specializing in cancer genetics testing and information services, offering one of the world’s most comprehensive oncology-focused test lists to clinicians to help them diagnose and treat cancer. The company’s pharmaceutical services division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life-changing treatments and experiences. We believe that, with our partners, we can help cancer patients today and the next person diagnosed tomorrow. In carrying out these obligations, NeoGenomics complies with all relevant data protection laws, and provides transparency and choice to patients regarding the handling and use of their data through our Site. Notice of Privacy Practicesand invested in leading-edge technologies to ensure the data we hold is secure at all times.

NeoGenomics is headquartered in Fort Myers, Florida and operates CAP-certified and CLIA-accredited laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical companies, integrated service delivery networks, managed care organizations throughout the United States, and pharmaceutical companies in Europe and Asia.

forward-looking statements

Certain information in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may generally be identified by the use of words such as “expect,” “expect,” “plan,” “could,” “will.” ”, “may”, “will”, “believe”, “estimate”, “expect”, “goal”, “project”, “plan”, “potential” and other words that have the same meaning. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those projected in the forward-looking statements as a result of the Company’s ability to continue acquiring new customers, responding to the effects of the COVID-19 outbreak, introducing new types of testing, merging acquisitions and implementing its business plan, as well as additional factors discussed under “Risk Factors” and elsewhere in the company’s annual report on Form 10-K filed with the SEC on February 25, 2021, as this information has been updated in subsequent SEC filings. As a result, this press release should be read in conjunction with the company’s periodic filings with the Securities and Exchange Commission. NeoGenomics routinely publishes information that may be of interest to investors in the “Investor Relations” section of its website at The company encourages investors and potential investors to consult the NeoGenomics website regularly for important information about NeoGenomics.

For more information, please contact:
NeoGenomics, Inc.
William B
Chief Financial Officer
T: 239.768.0600×2426

source: NeoGenomics, Inc.

View the source version on

Leave a Comment